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Cancer arises as a consequence of cumulative disruptions to cellular growth control with Darwinian
selection for those heritable changes that provide the greatest clonal advantage. These traits can be
acquired and stably maintained by either genetic or epigenetic means. Here, we explore the ways in
which alterations in the genome and epigenome influence each other and cooperate to promote
oncogenic transformation. Disruption of epigenomic control is pervasive in malignancy and can
be classified as an enabling characteristic of cancer cells, akin to genome instability and mutation.Introduction
Cancer develops through successive disruptions to the controls
of cellular proliferation, immortality, angiogenesis, cell death,
invasion, and metastasis. This evolutionary process requires
new malignant traits to be stably encoded so that oncogenic
events can accumulate in clonal lineages. Genetic mechanisms
of mutation, copy number alteration, insertion, deletion, and
recombination are particularly well suited as vehicles of persis-
tent phenotypic change. For this reason, cancer has long been
viewed as a disease based principally on genetics. Nevertheless,
genetic events occur at low frequency and are thus not a partic-
ularly efficient means for malignant transformation. Some cancer
cells overcome this bottleneck by acquiring DNA repair defects,
thus boosting the mutation rate. Mechanisms of epigenetic
control offer an alternative path to acquiring stable oncogenic
traits. Epigenetic states are flexible yet persist through multiple
cell divisions and exert powerful effects on cellular phenotype.
Although cancer cells have long been known to undergo epige-
netic changes, genome-scale genomic and epigenomic anal-
yses have only recently revealed the widespread occurrence of
mutations in epigenetic regulators and the breadth of alterations
to the epigenome in cancer cells (You and Jones, 2012). It is now
clear that genetic and epigenetic mechanisms influence each
other and work cooperatively to enable the acquisition of the
hallmarks of cancer (Hanahan and Weinberg, 2011).
Shaping the Epigenome
Epigenetic mechanisms allow genetically identical cells to
achieve diverse stable phenotypes by controlling the transcrip-
tional availability of various parts of the genome through differen-
tial chromatin marking and packaging. These embellishments
include direct DNA modifications, primarily CpG cytosine-5
methylation (Jones, 2012), but also hydroxylation, formylation,
and carboxylation (Ito et al., 2011), as well as nucleosome occu-
pancy and positioning (Gaffney et al., 2012; Valouev et al., 2011),
histone variants, and dozens of different histone modifications
(Tan et al., 2011b), interacting proteins (Ram et al., 2011), and
noncoding RNAs (Fabbri and Calin, 2010; Lee, 2012). These38 Cell 153, March 28, 2013 ª2013 Elsevier Inc.epigenetic marks do not act in isolation but form a network of
mutually reinforcing or counteracting signals. Genome-scale
projects charting the human epigenome are rapidly extending
our understanding of epigenetic marks and how they interact
(Adams et al., 2012; Dunham et al., 2012; Ernst et al., 2011).
A key facet of epigenetics is that these marks can be stably
maintained yet adapt to changing developmental or environ-
mental needs. This delicate task is accomplished by initiators,
such as long noncoding RNAs, writers, which establish the
epigenetic marks, readers, which interpret the epigenetic marks,
erasers, which remove the epigenetic marks, remodelers, which
can reposition nucleosomes, and insulators, which form bound-
aries between epigenetic domains. Epigenetic writers are
directed to their target locations by sequence context, existing
chromatin marks and bound proteins, noncoding RNAs, and/or
nuclear architecture. Thosemarks are then recognized by reader
proteins to convey information for various cellular functions. The
establishment, maintenance, and change of epigenetic marks
are intricately regulated, with crosstalk among the marks and
writers to help guide changes to the epigenetic landscape.
DNA Methylation
De novo methylation of DNA is catalyzed by the enzymes
DNMT3A and DNMT3B and is then maintained by the major
DNAmethyltransferaseDNMT1,with participation fromDNMT3A
andDNMT3B (Jones and Liang, 2009). DNAmethylation patterns
are guided in part by primary DNA sequence context (Cedar and
Bergman, 2012; Lienert et al., 2011) and are influenced by germ-
line variation (Gertz et al., 2011; Kerkel et al., 2008). Much of the
mammalian genome consists of vast oceans of DNA sequence
containing sparsely distributed but heavily methylated CpG
dinucleotides, punctuated by short regions with unmethylated
CpGs occurring at higher density, forming distinct islands in the
genome (Bird et al., 1985). These CpG islands (CGIs) are pro-
tected from DNA methylation in part by guanine-cytosine (GC)
strand asymmetry and accompanying R loop formation (Ginno
et al., 2012) and possibly also by active demethylation mediated
by the TET family members (Williams et al., 2012). The unmethy-
lated state of CpG islands in the germline, alongwith biased gene
Figure 1. Representative Epigenetic States
Examples of representative epigenetic states are shown for several typical categories of genes and in different cellular contexts.
(A) CpG-poor promoters are often tissue specific and/or reside in inducible genes that can be readily turned on or off. Transcription factor (TF) binding initiates
nucleosome-depleted regions (NDR) at regulatory elements and at the promoter.
(B) Many genes with CpG island promoters are constitutively expressed housekeeping genes.
(C) Some genes with CpG island promoters, such as TF master regulators of differentiation and development, are repressed by the Polycomb complexes in stem
cells and are kept in a bivalent state with both active and repressive marks.
(D) Polycomb targets in stem cells are predisposed to cancer-associated promoter hypermethylation. Repressive marks are shown in red, and active marks are
shown in blue.conversion, helps to preserve CpG islands despite ongoing attri-
tion of methylated CpG dinucleotides by cytosine deamination
throughout most of the genome (Cohen et al., 2011). Transition
zones between CpG islands and CpG oceans are called CpG
shores and display more tissue-specific variation in DNAmethyl-
ation (Irizarry et al., 2009). CpG islands span the transcription
start sites of about half of the genes in the human genome, largely
representing genes that are either actively expressed or poised
for transcription (Figure 1).
Methylated DNA is recognized by methyl-CpG binding
domains (MBD) or C2H2 zinc fingers. The MBD-containing
DNA methylation readers include MBD1, MBD2, MBD4, and
MeCP2, whereas Kaiso (ZBTB33), ZBTB4, and ZBTB38 proteins
use zinc fingers to bind methylated DNA. MBDs and Kaiso are
believed to participate in DNA methylation-mediated transcrip-tional repression of tumor suppressor genes with promoter
DNA methylation.
Histone Modifications
Posttranslational modifications of histones are coordinated by
counteracting histone methyltransferases (HMTs) and demethy-
lases (e.g., KDMs), histone acetyltransferases (HATs) and de-
acetylases (HDACs), and writers and erasers of phosphorylation,
as well as many other modifications (Chi et al., 2010; Tan et al.,
2011b). These histone modifiers generally act in complexes,
such as the repressive Polycomb (PcG) and activating Trithorax
(TrxG) group complexes, which counterbalance each other in the
regulation of genes important for development but which have
also been implicated in cancer (Mills, 2010). Polycomb repres-
sive complexes (PRCs) are guided to their targets in part by
intrinsic signals in the genome sequence (Ku et al., 2008; TanayCell 153, March 28, 2013 ª2013 Elsevier Inc. 39
Figure 2. Histone H3 Lysine Writers, Erasers, and Readers
Although many other important histone modifications also occur, only major histone H3 lysine modifications (Ac: Acetylation; me1: monomethylation;
me3: trimethylation) with well-defined functions are shown above a representative gene. The distribution of the marks is shown as colored bars and wedges to
indicate approximate abundance. Repressive marks are shown in red, and active marks are shown in blue. Epigenetic regulators are listed to the right of each
mark. Acetylation across different lysines shares writers and erasers, whereas methylation usually has dedicated enzymes. Readers (which can also be writers
and erasers themselves) recognize different chromatin states and propagate the signal in various ways, including self-reinforcement or crosstalk, transcriptional
activation or repression, or DNA repair. Crosstalk can also occur between histonemodification and DNAmethylation becauseDNMT3A,DNMT3L, andUHRF1 all
contain reader domains for chromatin states.et al., 2007). The histone H3K27me3 mark deposited by Poly-
comb repressive complex 2 (PRC2) provides docking sites for
PRC1, whose enzymatic core unit RING1B monoubiquitinylates
histone H2A at lysine 119 (H2AK119ub1), thereby blocking RNA
polymerase II elongation. The Trithorax group complex, contain-
ing MLL, which lays down the H3K4 methylation mark, counter-
acts Polycomb function. The transcription factors encoding
master regulators of differentiation and development are tar-
geted by PRC2 in embryonic stem cells and are held in a bivalent
chromatin state poised for transcription, with both the activating
H3K4me3 and the repressive H3K27me3 (Bernstein et al., 2006)
(Figure 1). During differentiation, the Trithorax demethylase
KDM6A/UTX removes the repressive H3K27me3 mark, allowing
transcription elongation to proceed for genes required in that
particular lineage, whereas genes not required in that cell type
lose the H3K4me3 active mark and undergo spreading of the40 Cell 153, March 28, 2013 ª2013 Elsevier Inc.H3K27me3 repressive mark (Hawkins et al., 2010). Other histone
marks have various readers with binding motifs, including bro-
modomain, PHD domain, chromodomain, and tudor domain
(Musselman et al., 2012) (Figure 2). Trithorax and Polycomb
complexes recruit HATs and HDACs, respectively, to counteract
each other, and the establishment of histone acetylation can
block Polycomb binding (Mills, 2010).
Histone Variants
Histone variants provide an additional layer of regulation. The
main histone genes have multiple copies in the genome and
are expressed during S phase. Single-copy variants are also ex-
pressed at other phases of the cell cycle and have distinct func-
tions and/or locations. H2A has the largest number of variants,
including H2A.Z, MacroH2A, H2A-Bbd, H2AvD, and H2A.X (Ka-
makaka and Biggins, 2005). The H3 variants include H3.3 and
centromeric H3 (CenH3 or CENP-A), as well as a mammalian
testis-specific histone H3 variant called H3.4. Nucleosomes con-
taining H3.3 and H2A.Z are located at dynamic regions requiring
nucleosome mobility and exchange, such as at actively ex-
pressed gene promoters (Jin et al., 2009). Wide presence of
H2A.Z in embryonic stem cells (Zhu et al., 2013) suggests prev-
alent chromatin exchange, which is consistent with the emerging
idea that the genome of ESC is generally kept highly accessible.
During differentiation, H2A.Z quickly redistributes. The mecha-
nisms of recruitment have not been fully delineated, but various
chromatin remodeler complexes and/or chaperones have been
shown to be involved. For example, SRCAP is involved in
H2A.Z loading into promoter/TSS, whereas H3.3 is loaded to
telomeric/pericentric regions by the ATRX/DAXX complex and
promoter/TSS by HIRA (Boyarchuk et al., 2011).
Nucleosome Positioning and Remodeling
The positioning of nucleosomes displays a weak 10 bp period-
icity associated with minor sequence composition fluctuations
in phase with the DNA helical repeat. Some nucleosomes are
more consistently positioned in phased arrays anchored by
sequence-specific binding of proteins such as CTCF or adjacent
to nucleosome-free regions at transcription start sites (Gaffney
et al., 2012; Valouev et al., 2011). CpG islands have been asso-
ciated with transcription-independent nucleosome depletion at
mammalian promoters (Fenouil et al., 2012). ATP-dependent
chromatin-remodeling complexes are responsible for sliding of
the nucleosomes, as well as insertion and ejection of histone oc-
tamers, processes that are important for transcriptional repres-
sion and activation, and other important cellular functions such
as DNA replication and repair. The remodeling complexes can
be divided into four families: SWI/SNF, CHD (chromodomain
and helicase-like domain), ISWI, and INO80 (including SWR1,
or SRCAP in mammals).
Insulators
The CCCTC-binding factor CTCF and its paralog CTCFL/BORIS
(expressed in the germline) are the only insulator proteins that
have been identified so far in vertebrates. CTCF has a strong
binding motif, and there is extensive overlap of the occupied
CTCF-binding sites among different cell types (Kim et al.,
2007). CTCF binds to enhancer blocking elements to prevent
enhancer interactions with unintended promoters (‘‘enhancer
blocking insulator’’) and also demarcates active and repressive
chromatin domains (‘‘barrier insulator’’).
Nuclear Architecture
The genome can be compartmentalized based on nuclear archi-
tecture and associated genomic features intomostly heterochro-
matic late-replicating regions attached to the nuclear lamina at
the nuclear periphery and more gene-rich early-replicating
regions closer to the nuclear interior (Dunhamet al., 2012;Meule-
man et al., 2013). Lamina-associated sequences (LASs) enriched
for a GAGA motif are bound by transcriptional repressors and
appear to contribute to the establishment of lamina-associated
domains (LADs) in the mammalian genome (Zullo et al., 2012).
Maintaining the Epigenetic State
The persistence of epigenetic traits in a growing tumor requires
that the epigenome be faithfully copied during cell division. The
chromatin structure is dismantled for passage of the replication
fork (RF). Newly synthesized DNA and histone octamers are then
assembled at the RF by chromatin assembly factor I (CAF1),which is tethered to the RF by PCNA. Similarly, the dedicated
maintenance DNA methyltransferase DNMT1 and the euchro-
matic H3K9 methyltransferase G9a, among other epigenetic
maintainers, are loaded to RFs and copy the epigenetic marks.
The Trithorax and Polycomb complexes are recruited prior to
replication and are distributed evenly to themother and daughter
strands at the RF, and they restore the correct marks on the
daughter molecules during G1 (Petruk et al., 2012). The his-
tone marks are self-reinforcing and self-propagating, as PcG,
SUV39H1/2, SETDB1, and TrxG all bind to the marks that they
are responsible for catalyzing via an intrinsic reader domain or
by interacting with a reader protein, thus helping to maintain
the epigenetic state. Nucleosomes containing methylated DNA
also stabilize DNMT3A/3B, which is a self-reinforcing mecha-
nism for DNA methylation maintenance (Sharma et al., 2011).
Disruption of Epigenetic Control in Cancer
Most studies of cancer epigenetics have focused on DNA meth-
ylation as the epigenetic mark that most easily survives various
forms of sample processing, including DNA extraction, and
even formalin fixation and paraffin embedding (Laird, 2010).
However, other epigenetic marks also undergo broad changes,
including long noncoding RNAs and miRNAs (Baer et al., 2013;
BaylinandJones,2011;DawsonandKouzarides, 2012;Sandoval
and Esteller, 2012) and histones, including loss of K16 acetyla-
tion and K20 trimethylation at histone H4 (Fraga et al., 2005;
Hon et al., 2012; Kondo et al., 2008; Seligson et al., 2005; Yama-
zaki et al., 2013). Lossof 5-methylcytosine incancer cellswasdis-
cussed more than three decades ago (Ehrlich and Wang, 1981),
with global DNAhypomethylation reported in cancer cell lines (Di-
ala and Hoffman, 1982; Ehrlich et al., 1982) and reduced levels of
DNA methylation found at selected genes in primary human
tumors compared to normal tissues (Feinberg and Vogelstein,
1983). The widespread loss of DNA methylation contrasted
starkly with the subsequent finding of hypermethylation of CpG
islands in cancer (Baylin et al., 1986), including of promoter
CpG islands of tumor-suppressor genes (Jones and Baylin,
2002). These seemingly contradictory findings have been widely
reported for many types of cancer (Baylin and Jones, 2011).
The causal relevance of epigenetic changes in cancer was
initially questioned, but this concern has now largely been laid
to rest. First, many known tumor-suppressor genes have been
shown to be silenced by promoter CpG island hypermethylation
(Jones and Baylin, 2002). Importantly, the finding that these
silencing events are mutually exclusive with structural or muta-
tional inactivation of the same gene, such as the case for
BRCA1 in ovarian cancer (Cancer Genome Atlas Research
Network, 2011) and for CDKN2A in squamous cell lung cancer
(Cancer Genome Atlas Research Network, 2012a), reinforces
the concept that epigenetic silencing can serve as an alternative
mechanism in Knudson’s two-hit hypothesis (Jones and Laird,
1999). Second, mouse models of cancer have been shown to
require epigenetic writers and readers for tumor development
(Laird et al., 1995; Prokhortchouk et al., 2006; Sansom et al.,
2003). Third, some DNA methylation changes appear to be
essential for cancer cell survival, suggesting an acquired addic-
tion to epigenetic alterations (De Carvalho et al., 2012). Finally,
a plethora of significantly mutated epigenetic regulators haveCell 153, March 28, 2013 ª2013 Elsevier Inc. 41
now been reported for many types of human cancer, as dis-
cussed further below.
Long-Range Coordinated Disruptions and Nuclear
Architecture
The genomeof undifferentiated embryonic stemcells is uniformly
heavilymethylated acrossCpGoceans, punctuated by unmethy-
lated CpG islands. As stem cells differentiate and proliferate,
the late-replicating lamin-associated domains (LADs) undergo
progressive loss of DNA methylation within CpG oceans, and
the LADs become recognizable as long partially methylated
domains (PMDs), which become even more strikingly demar-
cated as hypomethylated domains in cancer cells (Berman
et al., 2012; Hansen et al., 2011; Hon et al., 2012; Lister et al.,
2009). This loss of DNA methylation is associated with an
increase of repressive chromatin with large organized chro-
matin-lysine-(K) modification regions (LOCKs) (Hansen et al.,
2011; Hon et al., 2012; Lister et al., 2009). CpG island hyperme-
thylation is enriched in the hypomethylated domains, suggesting
that these two eventsmay bemechanistically linked but confined
to distinct areas of the genome near the nuclear periphery (Ber-
man et al., 2012). These long regions of DNA hypomethylation
and repressive chromatin are consistent with prior reports of
coordinated epigenetic silencing events located across mega-
base distances, a phenomenon termed long-range epigenetic
silencing (LRES) (Clark, 2007; Coolen et al., 2010).
It is noteworthy that the euchromatic part of the genome asso-
ciated with the interior of the nucleus is generally much more
epigenetically stable during cell differentiation, aging, and malig-
nant transformation. However, loss of the DNA methyltrans-
ferase Dnmt3a can promote tumor progression with uniform
hypomethylation across the genome andmoderate deregulation
of genes in euchromatic regions (Raddatz et al., 2012).
Disruption of Differentiation and Development
Differences between cell types are guided by the expression of
tissue-specific transcription factors and consolidation of associ-
ated epigenetic states. Therefore, the epigenome of a cancer cell
is determined in part by the cell of origin for that cancer and in-
cludes passenger hypermethylation events at genes not required
in that particular lineage (Sproul et al., 2012). Epithelial to mesen-
chymal transition (EMT) of cancer cells is partly under reversible
epigenetic control (De Craene and Berx, 2013). For example,
primary breast tumors display heterogeneous and unstable
silencing of the CDH1 (E-cadherin) gene, which facilitates the
plasticity required during extravasation, metastasis, and estab-
lishment of a solid tumor at the metastatic site (Graff et al., 2000).
It has long been debated whether cancer cells arise by dedif-
ferentiation or instead originate from stem cells or early progen-
itors by a differentiation block. Polycomb repressors mark genes
in stem cells encoding master regulators of differentiation and
development, poised to either be turned on to coordinate differ-
entiation of a lineage or to be fully repressed if it is not needed in
that particular lineage (Bernstein et al., 2006). These genes occu-
pied by Polycomb repressors in stem cells are particularly prone
to acquiring CpG island hypermethylation during cell prolifera-
tion, aging, and particularly malignant transformation (Ohm
et al., 2007; Schlesinger et al., 2007; Teschendorff et al., 2010;
Widschwendter et al., 2007) (Figure 1). Although the genes
affected by this process are primarily those not required or42 Cell 153, March 28, 2013 ª2013 Elsevier Inc.expressed in that particular cell lineage, cancer cells do also
show evidence of silencing of genes essential for differentiation
of their cell of origin (Berman et al., 2012; Easwaran et al.,
2012; Gal-Yam et al., 2008; Mohn et al., 2008; Teschendorff
et al., 2010). This predisposition of Polycomb target genes to
aberrant permanent epigenetic silencing is consistent with
a model in which stem cells slowly acquire irreversible silencing
of poised master regulators required for successful differentia-
tion. As a consequence, some stem cells lose their ability to
properly differentiate while retaining their self-renewal capabil-
ities and become attractive candidates for malignant transfor-
mation by subsequent genetic and epigenetic events. One
provocative implication of this model is that the first steps of
oncogenesis may in some cases be an epigenetic defect
affecting the differentiation capabilities of stem cells, as
opposed to a gatekeeper mutation.
Hematopoietic cell lineages and their corresponding malig-
nancies also offer insights into the role of epigenetics in differen-
tiation and transformation. For example, the DNMT3A gene is
commonly mutated in human cases of acute myeloid leukemia
(AML) (Ley et al., 2010; Yan et al., 2011), whereas loss ofDnmt3a
in mice progressively impairs hematopoietic stem cell differenti-
ation (Challen et al., 2012), suggesting that epigenetic perturba-
tion can lead to differentiation block and subsequent malignant
transformation.
CpG Island Methylator Phenotypes
Aberrant DNA methylation of promoter CpG islands in cancer
was initially viewed as a spontaneous or stochastic event with
selection for functionally relevant silencing events. However,
the discovery of cases of colorectal cancer with an exceptionally
high frequency of CpG island hypermethylation suggested a
coordinated event, possibly attributable to an epigenetic
control defect. This phenomenon was referred to as a ‘‘CpG
island methylator phenotype’’ (CIMP) (Toyota et al., 1999),
analogous to the mutator phenotypes observed in mismatch
repair-deficient cancers. Although the existence of CIMP sub-
sets of cancer was initially disputed (Yamashita et al., 2003),
more recent genome-scale analyses have unambiguously docu-
mented distinct epigenetic subtypes for some types of cancer,
such as colorectal cancer (Hinoue et al., 2012; Cancer Genome
Atlas Network, 2012b) and glioblastoma (Noushmehr et al.,
2010), and not for others, such as serous ovarian cancer (Cancer
Genome Atlas Research Network, 2011). The most distinct
examples of CIMP show exceptionally strong associations with
other molecular or pathological features of the tumors, lending
further validity to the biological relevance to this classification.
For example, colorectal CIMP is very tightly associated with
the V600E mutation of the BRAF oncogene (Weisenberger
et al., 2006), whereas glioma CIMP (G-CIMP) is exceptionally
tightly associated with mutation of the IDH1 gene (Noushmehr
et al., 2010). In the case of G-CIMP, IDH1 mutation appears to
be a causal contributor to the phenotype (Turcan et al., 2012),
whereas BRAF mutation does not appear to be directly impli-
cated in colorectal CIMP (Hinoue et al., 2009). The affected
gene subsets differ between colorectal CIMP and glioblastoma
G-CIMP, and their predisposition to aberrant methylation
appears to be distinct from the susceptibility of stem cell poly-
comb targets in lamin-attachment domains (Hinoue et al.,
2012), which is generally not restricted to cancer subtypes.
Despite a clear rationale for the association of IDH1 mutation
with G-CIMP, the mechanistic basis for the coordinated hyper-
methylation events in most cases of CIMP is unknown and will
remain an active area of investigation.
Epigenetic Influences on Genomic Integrity
Mutation rates vary strikingly across the genome, with strong
local influences of base composition on single nucleotide varia-
tion (SNV) and regional effects of sequence composition, chro-
matin structure, replication timing, transcription, and nuclear
architecture, among others, on both SNVs and structural alter-
ations (Hodgkinson and Eyre-Walker, 2011). Despite widespread
misuse of the term in the literature, it should be recognized that
mutation rates of a tumor cannot be inferred directly from
observed mutation numbers or frequencies in a tumor without
consideration of the number of cell divisions that have occurred
since a shared reference genome, although comparisons across
the genome obviate the need for Luria-Delbru¨ck fluctuation
modeling and analysis. Epigenetic mechanisms can influence
both the rates at which lesions arise and the rates at which they
are repaired. For example, the epigeneticmark 5-methylcytosine
undergoes spontaneous deamination at higher rates than do
unmethylated cytosines (Wang et al., 1982), whereas epigenetic
silencing of theMLH1mismatch repair gene increases mutation
frequencies by several orders of magnitude, providing an adap-
tive advantage to mismatch repair-deficient cancer cells.
Unmethylated and methylated cytosine residues both under-
go spontaneous hydrolytic deamination but yield uracil and
thymine, respectively. Uracil is not a normal constituent base in
DNA and is repaired much more efficiently than thymine in a
mismatch with guanine. As a consequence, the rate of C-to-T
mutations in the context of CpG dinucleotides, most of which
contain methylated cytosines, is about 10-fold higher than any
other SNV in the human genome (Hodgkinson and Eyre-Walker,
2011). This effect is particularly pronounced in highly proliferative
tissues because deamination of 5-methylcytosine in the parent
strand just prior to DNA replication results in a full T:A base
substitution that is not recognizable as a lesion for repair.
Approximately a quarter of all TP53 mutations in human cancer
are thus attributable to this epigenetic mark (Olivier et al., 2010).
Regional Effects of Chromatin Organization
Chromatin regulators play a role in maintaining genomic integrity
(Papamichos-Chronakis and Peterson, 2013), and regional chro-
matin structure has a major impact on mutation frequencies.
Megabase regions of repressive chromatin, represented by the
H3K9me3 mark, are positively correlated with single-nucleotide
variations in cancer (Schuster-Bo¨ckler and Lehner, 2012),
whereas open chromatin associated with DNase I hypersensitive
sites (DHS) have a lower inferred mutation rate, but this is partly
due to evolutionary constraints on this compartment (Hodgkin-
son and Eyre-Walker, 2011). Transcription-coupled repair may
also play a role in suppressing observed mutation frequencies
in gene-rich euchromatic regions.
Other types of mutation and structural change also appear to
be associated with chromatin states. For example, retrotranspo-
sition occurs more frequently in hypomethylated regions (Lee
et al., 2012). Genes resistant to cancer-associated hypermethy-lation are more likely to have SINE and LINE retrotransposons
near their transcription start sites than methylation-prone genes
(Este´cio et al., 2010). Severe hypomethylation appears to be
associated with genomic instability. Mouse models of DNA
methyltransferase deficiency display chromosomal instability
(Eden et al., 2003), and germline mutations of the DNMT3B
gene cause ICF syndrome, characterized by centromeric insta-
bility (Okano et al., 1999). Indeed, areas of hypomethylation in
the human germline showed higher frequencies of structural
mutability (Li et al., 2012). DNA breakpoints associated with
somatic copy number alterations are also enriched in hypome-
thylated domains (De and Michor, 2011).
Epigenetic Influences on DNA Repair
Depletion of DNA methyltransferases causes increased micro-
satellite instability (Guo et al., 2004; Kim et al., 2004), destabiliza-
tion of repeats (Dion et al., 2008), and dramatically increased
telomere length, telomeric recombination, and alternative telo-
mere lengthening (Gonzalo et al., 2006). These effects of DNA
methyltransferase depletion appear to be mediated in part by
a drop in DNA repair proteins as part of DNA damage response
(Loughery et al., 2011). The Dnmt1 protein has also been shown
to be recruited to areas of irradiation-induced DNA damage,
possibly to facilitate repair of epigenetic information following
DNA repair (Mortusewicz et al., 2005). It is increasingly appreci-
ated that chromatin can serve as a cellular sensor for DNA
damage and other genomic events (Johnson and Dent, 2013).
Epigenetic silencing of DNA repair genes such as MLH1,
MGMT, BRCA1, WRN, FANCF, and CHFR can boost mutation
rates and promote genomic instability in cancer cells (Toyota
and Suzuki, 2010). Familial cases of tumors with microsatellite
instability (MSI) in Lynch syndrome result from germline muta-
tions in mismatch repair genes, primarily MSH2 and MLH1.
However, most MSI-high tumors arise from an epigenetic defect
in sporadic cases of cancer. Approximately 15% of sporadic
cases of colorectal cancer display MSI as a consequence of
epigenetic silencing of the MLH1 mismatch repair gene by
promoter CpG island hypermethylation (Herman et al., 1998) in
the context of CIMP (Toyota et al., 1999; Weisenberger et al.,
2006). MSI caused by epigenetic silencing of MLH1 has also
been reported in other types of cancer, including about a quarter
of sporadic endometrial cancers (Simpkins et al., 1999). Germline
variants of MLH1 and MSH2 can predispose to extensive
somatic epigenetic silencing of thesegenes and thereby increase
cancer risk (Hitchins et al., 2011; Ligtenberg et al., 2009). Such
familial cases of systemic epigenetic abnormalities can mas-
querade as germline transmission of epigenetic defects. True
transgenerational epigenetic inheritance is evident in genomic
imprinting and in mouse models but has been difficult to demon-
strate directly in human populations, although there is indirect
evidence for its existence (Daxinger and Whitelaw, 2012).
The O6-Methylguanine DNA methyltransferase (MGMT) en-
zyme repairs O6-alkylated guanine residues in genomic DNA.
O6-methylguanine pairs with thymine and would lead to a
G-to-A transition during DNA replication if left unrepaired.
MGMT promoter methylation in colorectal cancer is associated
with G-to-A mutations in KRAS (Esteller et al., 2000b) and in
TP53 (Esteller et al., 2001). Alkylating agents such as temozolo-
mide are the current standard of care for malignant glioblastomaCell 153, March 28, 2013 ª2013 Elsevier Inc. 43
Figure 3. Genetic Alterations in Epigenetic Regulators
Mutations and other genetic alterations reported for selected epigenetic regulators are shown for various types of human cancer in a heatmap. Malignancies are
grouped by epithelial, hematological, and other cancers. Mutations, represented by colored cells, are deemed loss of function (blue) unless evidence for gain of
function (either hypermorphic or neomorphic, red) has been shown. Other genetic alterations are plotted with different symbols, with a slash indicating trans-
location events and a dot indicating copy number alterations. Translocations that generate oncogenic fusion proteins are represented in red as well. Themutation
(legend continued on next page)
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(GBM) but are counteracted by MGMT-mediated repair of the
alkylation damage. Epigenetic silencing of MGMT by promoter
CpG island hypermethylation inactivates this repair pathway
and renders the tumor more sensitive to the temozolomide treat-
ment (Esteller et al., 2000a; Hegi et al., 2005).
A Genetic Basis for Epigenetic Disruption in Cancer
The discovery of mutations in SMARCB1/SNF5 driving malig-
nant rhabdoid tumors first introduced genetic disruption of
epigenetic control as a mechanism of oncogenesis (Versteege
et al., 1998). Mutations in epigenetic regulators continued to
emerge from subsequent cancer studies and have surged in
recent large-scale sequencing efforts (Figure 3). Epigenetic
control genes are mutated in about half of hepatocellular carci-
nomas (Fujimoto et al., 2012) and bladder cancer (Gui et al.,
2011) and represent 6 of the 12 most significantly mutated
genes in medulloblastoma (Pugh et al., 2012). It is conceivable
that disruption of epigenetic control by mutation of a key regu-
lator has the capacity to cause widespread changes to the
transcriptome, multiplying the effect of the single genetic alter-
ation. It should be recognized that some of the mutations
reported for epigenetic regulators may be passenger events,
particularly in tumors with high background mutation rates.
Therefore, we have emphasized hot spot mutations and genes
recurrently mutated at significant frequencies. We focus here
on somatic mutations, but germline variations have also been
shown to play a role in cancer. For example, germline muta-
tions in BAP1 have been found to be linked to a tumor pre-
disposition syndrome characterized by melanocytic tumors,
mesothelioma, and uveal melanoma (Testa et al., 2011; Wies-
ner et al., 2011), and rare germline allelic forms of PRDM9
have been found to be associated with childhood leukemia
(Hussin et al., 2013).
DNA Methylation Writers and Erasers
The DNA methyltransferase DNMT3A is recurrently mutated in
AML and other myeloid malignancies (Ley et al., 2010; Yan
et al., 2011), as well as T cell lymphoma (Couronne´ et al.,
2012). The mutations often occur at a R882 hot spot but never-
theless likely reflect loss of function of DNMT3A. Mutations in
the DNA methylation eraser TET2 have also been identified in
the same cancer types (Abdel-Wahab et al., 2009; Langemeijer
et al., 2009; Quivoron et al., 2011), and bone marrow from
patients with TET2 mutations shows reduced levels of 5hmC
(Ko et al., 2010). The isocitrate dehydrogenases IDH1 and
IDH2 are also recurrently mutated in AML. IDH1 enzymes with
the R132 hot spot mutation and IDH2 enzymes containing
R140 or R172 mutations have lost the ability to produce a-keto-
glutarate (a-KG) but instead convert a-KG to an aberrant
metabolite 2-hydroxyglutarate (2-HG), a competitive inhibitor
of a-KG-dependent dioxygenases, such as the TETs and
JmjC-domain-containing histone demethylases (Lu et al., 2012;
Xu et al., 2011). IDH1/2 mutations are mutually exclusive withfrequencies, represented by the darkness of the shade, are based on recent w
exome studies are not available or have a small sample size. Different subtypes
certain mutations may only represent one subtype. Cells showing no entry may re
covered with whole-genome/exome studies (e.g., breast cancer) might have fe
instable (MSI CRCs are excluded due to the high background mutation rate); DLTET2 mutations in AML, which is consistent with the inhibitory
effect of 2-HG on TETs as a mediator of the effects of IDH1/2
mutations (Figueroa et al., 2010; Weissmann et al., 2012). The
same hot spot mutation for IDH1 and, less often, IDH2, is also
found in gliomas and glioblastomas. Both glioblastomas with
IDH1 mutations (Noushmehr et al., 2010) and cases of AML
with mutation of IDH1 or IDH2 (Figueroa et al., 2010) display
CpG island methylator phenotypes.
Histone Gene Mutations
Mutations in histone variants H3.3 (H3F3A) or sometimes H3.1
(HIST1H3B) have been found in pediatric (Schwartzentruber
et al., 2012; Wu et al., 2012) and adult brain tumors (Sturm
et al., 2012) with K27M and G34R or G34V mutation hot spots.
Tumors with G34 mutations display extensive DNA hypomethy-
lation, particularly in subtelomeric regions (Sturm et al., 2012),
perhaps contributing to alternative lengthening of telomeres
(ALT) (Schwartzentruber et al., 2012). Mutations were also
observed in the ATRX and DAXX genes, encoding proteins
responsible for loading of the H3.3 variant into the telomere
region (Schwartzentruber et al., 2012). Pancreatic neuroendo-
crine tumors (PanNETs) with ATRX and DAXX mutations also
exhibit ALT (Heaphy et al., 2011). Because this phenotypic effect
is associated with an H3.3 loading defect, the G34 mutations
may also interfere with H3.3 loading. In contrast, tumors with
K27M mutations did not display ALT, and these mutations may
instead mimic dimethylated lysine 27, a repressive Polycomb
mark, given that methionine is a natural mimic of this epigenetic
mark (Hyland et al., 2011). H3.3 G34R mutations have also been
reported in primitive neuroectodermal tumors of the central
nervous system (CNS) (Gessi et al., 2013), mirroring the defect
in the ATRX-DAXX-H3.3 axis in other brain tumors and PanNETs.
Mutations in HIST1H3B and HIST1H1C have been found in
diffuse large B cell lymphoma (DLBCL), although the mutations
do not occur in clusters (Lohr et al., 2012; Morin et al., 2011).
Thesemight be functionally different from the hot spot mutations
seen in brain tumors. Focal deletion of a histone gene cluster
at 6p22 is seen in near-haploid cases of acute lymphoblastic
leukemia (Holmfeldt et al., 2013).
Histone Methylation Writers
The MLL gene, encoding one of the H3K4 methyltransferases,
has more than 50 translocation fusion partners in different line-
ages of leukemia. These rearrangements account for 80% of
the cases of infant leukemia and 5%–10% of adult leukemia
cases and are generally associated with poor prognosis (Tan
et al., 2011a). The primary mechanism has been attributed to
the recruitment of inappropriate epigenetic factors to MLL
targets by fusions between recruitment proteins and the DNA-
binding N terminus of MLL. Target genes for these recruited
complexes include the HOX genes, particularly HOXA9, whose
upregulation is a key feature of MLL leukemia. MLL regulates
the expression of HOX genes in normal pluripotent cells, but
the oncogenic fusion proteins keep them from being turned offhole-genome/exome studies, with adjustments made where whole-genome/
of lung cancers are combined without adjusting for subtype prevalence, and
present false negatives in our curation or in the literature. Cancer types highly
wer false negatives than those that are not. MSS/MSI, microsatellite stable/
BCL, diffuse large B cell lymphoma; FL, follicular lymphoma.
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during differentiation and therefore impart stem-cell-like proper-
ties. Targeted therapeutic strategies are emerging for AML with
MLL fusions, including inhibition of menin (encoded by MEN1),
DOT1L, PRMT1, the histone acetylation reader BRD4, and
LSD1 (Zeisig et al., 2012). In addition to the translocations,
loss-of-function mutations of MLL-MLL3 have been reported in
many different types of cancer, including AML—possibly another
way of disturbing the temporal control at promoters associated
with pluripotency. MLL2 is mutated at very high frequency in
B cell follicular lymphoma and diffuse large B cell lymphoma,
which is consistent with the gain-of-function mutations of
EZH2 in the same tumor types.
Although menin is critical to the oncogenic effects of MLL
fusion proteins in AML (Yokoyama and Cleary, 2008), loss-of-
function mutations have been found in PanNETs (Jiao et al.,
2011), which is consistent with a tumor-suppressor role, sug-
gesting that cellular context is important.
The recurrent t(5;11)(q35;p15.5) translocation in AML results in
the fusion of the H3K36 methyltransferase NSD1 to nucleoporin-
98 (NUP98), with elevated levels of H3K36me3 levels at HOXA
genes and accompanying transcriptional activation. Transloca-
tions involving another dedicated H3K36 methyltransferase
WHSC1/MMSET/NSD2 are seen in 20% of multiple myelomas.
AnotherH3K36methyltransferase,SETD2, is recurrentlymutated
in clear cell renal cell carcinomas (ccRCC) (Dalgliesh et al., 2010).
A recent study reconstructed the phylogenetic structure of
molecular events in ccRCC with multiple spatially separated
samples from the same tumors (Gerlinger et al., 2012). In both
of the two patients studied, distinct SETD2-inactivating muta-
tions were found in different parts of the same tumor. Immuno-
histochemistry staining confirmed H3K36me3 loss in all the
mutant tumors. This convergent somatic evolution indicates
that failure to establish H3K36 methylation marks provides a
strong selective advantage relatively late in ccRCC progression.
A similar molecular convergence was found for KDM5C, an
H3K4 demethylase, in one of the two patients. This, together
with recurrent mutations in other epigenetic regulators, shows
that epigenetic dysregulation, often mediated by genetic events,
is important in advanced ccRCCs.
EZH2, the writer for the H3K27 methylation mark associated
with Polycomb repression, has long been viewed as an onco-
gene in cancer. Indeed, gain-of-function mutations are seen in
lymphomas. However, loss-of-function mutations in this gene
have recently been described in other cancers.We discuss these
divergent effects of EZH2mutations and other alterations to this
pathway in more detail later (Figure 4).
Histone Methylation Erasers
Consistent withEZH2 overexpression in various solid tumors, the
corresponding eraser KDM6A/UTX is mutated in more than a
dozen tumor types, with the highest frequency in bladder (Gui
et al., 2011; van Haaften et al., 2009). The H3K9 demethylase
KDM4C/GASC1 is amplified in breast cancer and has been
shown to drive transformation (Liu et al., 2009; Rui et al., 2010).
Ectopic expression of this putative oncogene in vitro causes an
efficient decrease of H3K9me3 (Cloos et al., 2006). Its coamplifi-
cation with JAK2 (Rui et al., 2010)—which phosphorylates
H3Y41 and prevents binding of H3K9 methylation reader HP1
to the H3K9 methylation mark—in lymphoma makes for an inter-46 Cell 153, March 28, 2013 ª2013 Elsevier Inc.esting example of a single genetic event hitting two possible
epigenetic regulators. Inhibiting the two coamplified and cooper-
ating gene products is efficient at killing these lymphoma cells.
Histone Acetylation Writers and Erasers
The counteracting HATs and HDACs are considered to be
promiscuous and often have important nonhistone substrates
such as TP53. There are three major families of HATs, namely
the CBP/P300, GNAT, and the MYST families. CREBBP is
mutated at high frequency in follicular lymphoma and DLBCL
(Morin et al., 2011; Pasqualucci et al., 2011) and in ALL (Mul-
lighan et al., 2011), particularly relapsed hyperdiploid ALL (Inthal
et al., 2012). Its paralog EP300 also undergoes frequent mutation
(Gayther et al., 2000; Gui et al., 2011; Pasqualucci et al., 2011;
Zhang et al., 2012) and loss of heterozygosity (LOH) in many
different epithelial cancers.
HATs have also been implicated in gene fusions. The
t(8;16)(p11;p13) translocation in AML fuses the N-terminal part
of MOZ, the founding member of the MYST HAT family, to the
major part of the CBP gene containing the acetylase domain.
MOZ has also been found to be involved in fusions with EP300
(Yang, 2004). These translocations generating chimeric onco-
proteins with the DNA-binding domain ofMOZ and the transcrip-
tion-activating domain of another coactivator are associated
with AML M5/M4. These results suggest that both disruption
and redirection of HAT could contribute to cancer.
Reports of mutations in HDACs are rare. Rather, HDACs are
often co-opted by other genetic alterations. A prime example is
the PML-RARa translocation, which is responsible for 95% of
the AML FAB-M3 (APL, acute promyelocytic leukemia) cases.
The leukemogenetic effect of this translocation is primarily
mediated through aberrant recruitment of N-CoR/HDAC re-
pressor complexes (Minucci and Pelicci, 2006). The retinoic
acid receptor-a (RARa) part binds to retinoic acid-responsive
elements (RAREs), whereas the PML moiety recruits the
HDAC-containing repressive complex. All-trans retinoic acid
(ATRA) targets RARa, dissociates these repressor complexes,
and effectively induces differentiation of the leukemic promyelo-
cytes.Combination therapy of ATRAandarsenic trioxide showed
excellent clinical response and turned APL into a highly curable
disease (Wang and Chen, 2008). Another fusion protein, PLZF-
RARa, blocks differentiation by a similar mechanism. However,
APL with this translocation is ATRA resistant due to the higher
affinity of thePLZFmoiety to theN-CoRcomplex, but a combina-
tion of ATRAwith HDAC inhibitors can fully reverse the transcrip-
tional repression and induce terminal differentiation for this type
of AML (Wang and Chen, 2008). Similarly, the RUNX1-ETO
fusion, the AML1-ETO fusion, and the CBF-MYH11 protein
from inv(16) all recruit HDACs, and efficacy of HDAC inhibitors
has been demonstrated for all three (Zeisig et al., 2012).
Epigenetic Readers
The epigenetic readers add another layer of control to the epige-
netic state by serving as interpreters of the epigenetic state and
relaying epigenetic signals. Many of the epigenetic writer/eraser/
remodelers have intrinsic reader domains or interact with
dedicated readers to sense the presence or absence of partic-
ular epigenetic marks. Translocations joining BRD4 or occasion-
ally BRD3—both readers of the BET bromodomain-containing
family—to almost the entire length of the NUT gene define
Figure 4. Genetic Disruption of Epigenetic Control at H3K27 in Cancer
The counteracting writer EZH2 and eraser KDM6A/UTX form a pair in regulating an important epigenetic mark, methylation at H3 lysine 27. EZH2 catalyzes the
methylation process with help from other components in PRC2, whereas KDM6A, part of the Trithorax complex, removes this repressivemark. The K27me3mark
attracts another Polycomb complex, PRC1, which ubiquitinates H2AK119, and thereby blocks PolII elongation. Another Polycomb complex, PR-DUB, is also
critical to the maintenance of the repression at a subset of the Polycomb genes, although it removes the H2AK119ub mark and thus counteracts PRC1 in that
regard. Mutations and genetic alterations spanning a wide spectrum of human cancers hit this epigenetic pathway. Solid tumors show possibly neomorphic
histone K27 mutations (mimicking H3K27me2), UTX mutation, EZH2 amplification, and/or overexpression due to genomic loss of the repressive microRNA
miR101, as well as amplification/overexpression of the PRC1member BMI1, and lymphoma exhibits gain-of-functionmutations of EZH2, which is consistent with
a gain of Polycomb repression (red boxes) in the affected malignancies. In contrast, myeloid malignancies and ALL, particularly early T cell precursor ALL, show
mutations that could sabotage Polycomb repression (blue boxes). Mouse models show that loss of BAP1, the enzymatic unit of PR-DUB, leads to myeloid
transformation, although BAP1 mutation in MDS is rare. Gray boxes indicate that the effect on H3K27me3 is not clear.a lethal, poorly differentiated pediatric tumor, NUT midline carci-
noma (NMC) (French et al., 2008). The BET family members
targetable by BET inhibitors (Filippakopoulos et al., 2010) are
lysine acetylation readers that bind transcriptionally active
chromatin as acetylated lysine readers and are targetable by
BET inhibitors (Filippakopoulos et al., 2010). Functional studies
show that the BRD-NUT fusion oncoprotein binds avidly to acet-
ylated histones, resulting in a differentiation block potentially by
interfering with transcriptional programs driving differentiation
(French et al., 2008). BRD3 is significantly mutated in lung
adenocarcinomas (Imielinski et al., 2012), and BRD8 is mutated
in liver cancer (Fujimoto et al., 2012). In addition, the plant home-
odomain (PHD)-domain containing gene PHF6 is recurrently
mutated in AML (Van Vlierberghe et al., 2011), and overall loss
of this gene (mutation and/or deletion) is observed in T-ALL
(Van Vlierberghe et al., 2010).Chromatin Remodelers
A large number of SWI/SNF complexes exist in mammals and
contribute to lineage- and tissue-specific gene expression
(Wilson and Roberts, 2011). The two major types of SWI/SNF
complexes are BAF (BRM containing, or SWI/SNF-A) and
PBAF (BRG1 containing, or SWI/SNF-B), defined by a core enzy-
matic unit being either SMARCA2 (BRM) or SMARCA4 (BRG1).
Those complexes also contain other core units, such as
SMARCB1/SNF5 and ARID1A/B—which are unique to BAF—
and PBRM1 and BRD7—which are unique to PBAF. Truncating
mutations in the SMARCB1 gene are very common in malignant
rhabdoid tumors (RTs) (Versteege et al., 1998), a rare yet lethal
tumor diagnosed in children. The biallelic nature of the inactiva-
tion fits with a tumor suppressor role for SMARCB1. Familial
cases of RTs are associated with inheritance of one defective
SMARCB1 allele. SMARCB1 is also mutated in a few otherCell 153, March 28, 2013 ª2013 Elsevier Inc. 47
cancers (Figure 1). SMARCA4 mutation is also seen in familial
cases of RT (Schneppenheim et al., 2010), indicating that it is
indeed SWI/SNF dysfunction that is responsible for RT develop-
ment. SMARCA4 is also mutated Burkitt’s lymphoma in a mutu-
ally exclusive manner with ARID1Amutations (Love et al., 2012),
again suggesting a driver role for SWI/SNF mutations. Recurrent
SMARCA4 mutation is also seen in lung cancer (Imielinski et al.,
2012) andmedulloblastoma (especially theWNT subtype) (Jones
et al., 2012; Parsons et al., 2011; Pugh et al., 2012; Robinson
et al., 2012).
ARID1Amutations have been found in more than ten different
tumor types, with the highest rate in the clear cell subtype of
ovarian cancer, where it is mutated in more than half of the
tumors (Jones et al., 2010; Wiegand et al., 2010). ARID1A is
also mutated in the endometrioid subtypes of ovarian (Wiegand
et al., 2010) and endometrial cancers (Guan et al., 2011).ARID1B
and ARID2 mutations are also seen in various cancer types,
including liver cancer (Fujimoto et al., 2012) and melanoma
(Hodis et al., 2012), among others. In addition, the polybromo-
containing PBRM1 in the PBAF complex was recently found to
be the second most mutated gene in clear cell renal cell carci-
nomas (Varela et al., 2011). Another SWI/SNF gene, SMARCE1,
is highly recurrently mutated in clear cell meningiomas (Smith
et al., 2013). The exceptionally high mutation rate of SWI/SNF
member in clear cell tumors from different tissues (ovary, kidney,
and meninges) highlights an interesting possible link between
clear cell tumors and SWI/SNF dysfunction.
ATRX, responsible for H3.3 incorporation at telomeres and
pericentric heterochromatin, is often mutated in PanNETs, the
second most common malignancy of the pancreas (Jiao et al.,
2011). Interestingly, there are also recurrent mutations in the
associated chaperone DAXX in the same cancer type, and the
two mutations are mutually exclusive. Mutations of these two
genes are also found in GBM, where they are mutually exclusive
with the H3F3A mutations described earlier, with any of these
three genes mutated in almost half of the tumors studied
(Schwartzentruber et al., 2012). These mutations all lead to alter-
native lengthening of telomeres associated with increased geno-
mic instability (Heaphy et al., 2011; Schwartzentruber et al.,
2012). With the possible exception of ATRX and DAXX, most of
the mutations in the SWI/SNF family members are not associ-
ated with genomic instability (Wilson and Roberts, 2011). Rather,
perturbed differentiation may be the major mechanism, as cells
from different lineages coexist within an individual rhabdoid
tumor.
The CHD family chromatin remodelers can be divided into
three classes: class I (CHD1/2), class II (CHD3/4, in the NuRD/
Mi-2/CHD complex), and class III (CHD5–9). The NuRD/Mi-2/
CHD complexes are unique in that they have core enzymatic
subunits with at least two distinct functions—ATP-dependent re-
modeling (CHD3 and CHD4), as well as histone deacetylase
(HDAC1 and HDAC2) functions (Lai and Wade, 2011)—and
therefore couple two epigenetic processes in one complex for
transcriptional repression. Their MBD and MTA subunits target
the complex to different parts of the genome by binding
methylated DNA (MBD) or other transcription factors (MTA) in
physiological and pathological conditions. For example, the
MTA-2-containing NuRD complex associates with TWIST in48 Cell 153, March 28, 2013 ª2013 Elsevier Inc.breast cancer, represses genes such as E-cadherin (CDH1),
and contributes to EMT. CHD4 is mutated in 17% of serous
endometrial cancer (Le Gallo et al., 2012). Of the other CHDs,
CHD1 is the second most frequently deleted gene in prostate
cancer, defining an ETS-negative subtype (Grasso et al., 2012),
with mutations reported as well (Berger et al., 2011).
Epigenetic Insulators
CTCF is located in 16q22.1 with LOH in breast and prostate
cancers (Filippova et al., 1998) and Wilms’ tumors (Mummert
et al., 2005). CTCF mutation has also been reported in breast
cancer (Filippova et al., 2002), and this mutation is found to be
significant in a cohort of 510 tumors (Cancer Genome Atlas
Network, 2012c). Rare mutations in this gene have also been re-
ported for prostate cancer (Filippova et al., 2002), Wilms’ tumor
(Filippova et al., 2002), AML (Dolnik et al., 2012), ALL (Mullighan
et al., 2011; Zhang et al., 2012), and endometrial cancers (Le
Gallo et al., 2012). The functional implications of CTCF dele-
tion/mutation, especially given the low frequency, have not
been fully delineated yet, but abrogation of proper insulation
might be one mechanism.
Genetic Disruption of a Central Epigenetic Control
Circuit
Figure 4 illustrates the diverse ways in which a central epigenetic
control circuit can be impacted in cancer. EZH2 catalyzes meth-
ylation at H3K27, as part of PRC2. Two other core subunits of
PRC2 are EED and SUZ12, and other components such as
JARID2 can be part of a PRC2 complex too. EZH2 has long
been thought to be oncogenic because it is overexpressed as
a result of amplification of EZH2 in breast, bladder, and other
cancers (Bracken et al., 2003), as well as genetic loss of
miR101, which represses EZH2 in prostate cancer (Varambally
et al., 2008). In linewith this view, gain-of-function hot spotmuta-
tions (Y641 and A677) in the SET domain of EZH2 have been
found in a significant portion of lymphomas (Lohr et al., 2012;
Morin et al., 2010, 2011; Pasqualucci et al., 2011). More convinc-
ingly, EZH2 amplification and overexpression in two of the
largest subgroups of medulloblastoma are mutually exclusive
with mutation of the H3K27 demethylase KDM6A, suggesting
that accumulation of H3K27me3 is a key step in these tumors
(Robinson et al., 2012).
On the other hand, loss-of-function mutations of EZH2 have
also been found in a series of myeloid malignancies, including
myelodysplastic syndrome (MDS), multiple myeloma, myelopro-
liferative neoplasms (MPN), and myelodysplastic/myeloprolifer-
ative neoplasms (MDS/MPN), as well as in head-and-neck
squamous cell carcinomas (HNSCCs) (Ernst et al., 2010; Niko-
loski et al., 2010; Stransky et al., 2011), suggesting that PRC2
can also act as a tumor suppressor. Mutually exclusive recurrent
deletion and loss-of-function mutations of EZH2 and SUZ12 in
T lineage acute lymphoblastic leukemia (T-ALL) (Ntziachristos
et al., 2012) and of all three PRC2 subunits in early T cell-
precursor ALL (Zhang et al., 2012) further substantiate a tumor
suppressor role for PRC2 function. Indeed, disruption of EZH2
is sufficient to induce T-ALL in mice (Simon et al., 2012). PRC2
component mutations are much more common in early T cell
precursor ALL, a lymphoblastic leukemia with myeloid features.
The Polycomb repressive deubiquitinase (PR-DUB) component
ASXL1 is also mutated in myeloid malignancies, and ASXL1
Figure 5. Interplay between the Cancer Genome and Epigenome
The genome and epigenome influence each other, as the genome provides the primary sequence information and encodes regulators of epigenetic states,
whereas the epigenome controls the accessibility and interpretation of the genome. Changes in one can influence the other, forming a partnership in producing
genetically or epigenetically encoded phenotypic variation subject to Darwinian selection for growth advantage and thus eventually achieving the hallmarks of
cancer (Hanahan and Weinberg, 2011). Genetic instability and mutation and epigenomic disruption can be considered enabling characteristics of cancer cells.mutation mediates myeloid transformation through loss of PRC2
repression (Abdel-Wahab et al., 2012), which is in line with the
observed loss of function of PRC2 members in myeloid disor-
ders. Mouse models also show that loss of BAP1, the enzymatic
unit of PR-DUB, leads to myeloid transformation (Dey et al.,
2012). This, together with a BAP1 catalytic mutation found in
a MDS patient lacking other MDS mutations (Dey et al., 2012),
further lends credibility to the idea that loss of Polycomb repres-
sion drives myeloid disorders, whereas in B cell lymphoma and
solid tumors, gain of Polycomb repression seems important.
EZH2 also exhibits PRC2-independent oncogenic activities.
For example, in castration-resistant prostate cancer, Akt-medi-
ated phosphorylation of EZH2 at S21 can shift EZH2 from
PRC2-dependent promoters to EZH2 ‘‘solo’’ promoters. ThisEZH2 activity is often associated with androgen receptor (AR)
and activates gene expression at these loci (Xu et al., 2012).
These complex ways in which the H3K27me3 axis is disrupted
in cancer suggest that differential therapeutic approaches
should be developed for (1) myeloid malignancies and early
T cell ALL, (2) lymphomas and some solid tumors, and (3)
possibly hormone-associated cancers. In particular, caution
should be used when considering EZH2 inhibitors for the first
group of tumors, which features genetic lesions leading to loss
of PRC2 repression.
Conclusions
It is clear that the cancer genome and epigenome influence each
other in amultitude of ways (Figure 5). They offer complementaryCell 153, March 28, 2013 ª2013 Elsevier Inc. 49
mechanisms to achieve similar results, such as the inactivation
of tumor-suppressor genes, including BRCA1, CDKN2A, VHL,
and RB1, by either deletion or epigenetic silencing, and they
can work cooperatively as in the case of CIMP and BRAFmuta-
tion in colorectal cancer, where CIMP appears to create a per-
missive context for BRAF mutation as early as in the precursor
lesion (Hinoue et al., 2009; Yamamoto et al., 2012).
Many questions and challenges remain. For example, the
explosion in the number of epigenetic regulator mutations
identified in human cancer has underscored the importance of
epigenetic control in tumor suppression, but the phenotypic
consequences of these mutations remain largely uncharacter-
ized. However, this plethora of newly identified mutations in
epigenetic regulators opens entirely new avenues of therapeutic
attack (Dawson and Kouzarides, 2012).
Another major question remaining in the field is the mecha-
nistic basis for some well-recognized examples of disruption of
epigenetic control, such as CIMP in colorectal cancer. Even in
the case of G-CIMP in gliomas and its very tight association
with IDH1 mutation, it is not clear what confers the gene speci-
ficity of the hypermethylation events. Correlated events such
as CIMP create other challenges as well. In contrast to most
mutations, CIMP-associated DNA methylation events are highly
correlated, with a large number of recurrent alterations that
appear to be passenger events without functional contribution
to the cancer process. This high degree of correlation precludes
the straightforward use of recurrence frequency among different
tumors as amain filter criterion in the identification of functionally
relevant epigenetic driver events. Therefore, the identification of
epigenetic drivers must rely more on the analysis of transcrip-
tional consequences, mutual exclusivity with other events in
the same pathway within a tumor, complementary mechanisms
of inactivation of the same gene in other tumors, and, most
importantly, functional experimental validation of an impact of
the epigenetic gene inactivation on cellular proliferation, immor-
tality, angiogenesis, cell death, invasion, or metastasis.
Cancer epigenetics and genetics may inform each other.
Genetics can shed light on the identity of epigenetic drivers by
revealing mutual exclusivity with genetic aberrations in the
same gene or pathway. Epigenetics may also provide insight
into genetic drivers in a similar fashion. In addition, the under-
standing of epigenetic networks provides a framework to inter-
pret the functional significance of lower-frequency drivers in
the same pathway. The high frequency of epigenetic regulator
mutations seen in various cancers, the hot spot nature of some
mutations found, mutual exclusivity between different mecha-
nisms affecting the same genes/pathways, clonal analysis high-
lighting convergent evolution, and validations in experimental
systems all attest to the importance of mutations in epigenetic
regulators in cancer and strengthen the concept that disruption
of epigenetic control is a common enabling characteristic of
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